Gan & Lee Pharmaceuticals Gets FDA Green Light for Phase I Clinical Trial of Insulin Aspart Biosimilar
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company based in China, has received...
Diabetes
Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...
Tonghua Dongbao Pharmaceuticals Launches Phase III Clinical Trial for Semaglutide Biosimilar in China
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced the commencement of a...
Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...
China Unveils Comprehensive 2030 Plan to Combat Diabetes
China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...
AstraZeneca’s Q2 2024 Results Highlight Strong Growth Across Therapies, Excluding Vaccines
AstraZeneca (NASDAQ: AZN), a UK-based biopharmaceutical company, has reported its financial results for the second...
Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial
Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...
Innovent Biologics’ Mazdutide Achieves Primary and Secondary Endpoints in Phase III T2D Trial
Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has announced...
NMPA Approves Chengdu Chipscreen’s Bilessglu for Type 2 Diabetes in Combination with Metformin
The National Medical Products Administration (NMPA) has granted approval for Shenzhen Chipscreen Biosciences Co., Ltd...
Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity
Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...
Novo Nordisk’s Awiqli Faces FDA Setback as BLA Draws Complete Response Letter
Novo Nordisk A/S (NYSE: NVO) announced that the U.S. Food and Drug Administration issued a...
Shenzhen Salubris Pharmaceuticals’ Fotagliptin Receives NMPA Approval for Type 2 Diabetes Treatment
Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a pharmaceutical company based in China, has announced...
Semaglutide Use Linked to Rare Eye Condition NAION in New Study
A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...
Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay
Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...
Jiangsu Hengrui’s Henagliflozin Gains Expanded Indication for Type 2 Diabetes Treatment in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
HighTide Therapeutics Completes Enrollment for Two Phase III Trials of T2DM Drug Candidate HTD1801
HighTide Therapeutics Inc., (HKG: 2511), a biopharmaceutical company based in China, has announced the completion...
Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
Hybio Pharmaceutical’s Biosimilar Liraglutide Gets Temporary FDA Nod Pending Patent Expiry
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Haisco Pharmaceutical Gets NMPA Green Light for Cofrogliptin to Treat Type 2 Diabetes
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received marketing approval...